Tianjin Tianyao Pharmaceuticals Co Ltd Asset Resilience Ratio
Tianjin Tianyao Pharmaceuticals Co Ltd asset resilience ratio. Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has an Asset Resilience Ratio of 0.00% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600488 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tianjin Tianyao Pharmaceuticals Co Ltd (2001–2015)
Asset resilience ratio of Tianjin Tianyao Pharmaceuticals Co Ltd from 2001 to 2015. This chart shows how Tianjin Tianyao Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Tianjin Tianyao Pharmaceuticals Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600488 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥128.80K | 0.0% |
| Total Liquid Assets | CN¥128.80K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Tianyao Pharmaceuticals Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Tianyao Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Tianyao Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Tianjin Tianyao Pharmaceuticals Co Ltd Asset Resilience Ratio by Year (2001–2015)
Tianjin Tianyao Pharmaceuticals Co Ltd asset resilience ratio by year from 2001 to 2015. The table below shows the annual Asset Resilience Ratio data for Tianjin Tianyao Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 4.95% | CN¥150.00 Million ≈ $21.95 Million |
CN¥3.03 Billion ≈ $443.85 Million |
+4.90pp |
| 2003-12-31 | 0.05% | CN¥758.82K ≈ $111.04K |
CN¥1.60 Billion ≈ $234.85 Million |
-17.21pp |
| 2002-12-31 | 17.26% | CN¥244.90 Million ≈ $35.84 Million |
CN¥1.42 Billion ≈ $207.65 Million |
+2.70pp |
| 2001-12-31 | 14.55% | CN¥165.06 Million ≈ $24.15 Million |
CN¥1.13 Billion ≈ $165.94 Million |
-- |
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more